These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

206 related articles for article (PubMed ID: 36998423)

  • 1. Supply and quality of colonoscopy according to the characteristics of gastroenterologists in the French population-based colorectal-cancer screening program.
    Koïvogui A; Vincelet C; Abihsera G; Ait-Hadad H; Delattre H; Le Trung T; Bernoux A; Carroll R; Nicolet J
    World J Gastroenterol; 2023 Mar; 29(9):1492-1508. PubMed ID: 36998423
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Post-colonoscopy colorectal cancer: A population-based cohort study of fecal occult blood test-positive colonoscopies.
    Denis B; Bertolaso A; Gendre I; Perrin P; Hammas K
    Clin Res Hepatol Gastroenterol; 2024 Feb; 48(2):102285. PubMed ID: 38246488
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Évaluation de la gravité du cancer colorectal dépisté dans le contexte de la crise sanitaire liée au COVID19 en région Ile-de-France].
    Koïvogui A; Abihsera G; Le Trong T; Ait-Hadad H; Bernoux A; Delattre H; Vincelet C; Caroll R; Nicolet J
    Rev Epidemiol Sante Publique; 2023 Oct; 71(5):102124. PubMed ID: 37451076
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Fecal occult blood test for colorectal cancer screening: an evidence-based analysis.
    Medical Advisory Secretariat
    Ont Health Technol Assess Ser; 2009; 9(10):1-40. PubMed ID: 23074514
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Detection of Colorectal Neoplasia in a Cohort Before and After the Change of Fecal Occult Blood Test in a French Colorectal Cancer Screening Program.
    Koïvogui A; Mab GL; Benamouzig R
    Am J Gastroenterol; 2018 Dec; 113(12):1891-1899. PubMed ID: 30337703
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cost-effectiveness of the faecal immunochemical test at a range of positivity thresholds compared with the guaiac faecal occult blood test in the NHS Bowel Cancer Screening Programme in England.
    Murphy J; Halloran S; Gray A
    BMJ Open; 2017 Oct; 7(10):e017186. PubMed ID: 29079605
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Faecal immunochemical tests versus guaiac faecal occult blood tests: what clinicians and colorectal cancer screening programme organisers need to know.
    Tinmouth J; Lansdorp-Vogelaar I; Allison JE
    Gut; 2015 Aug; 64(8):1327-37. PubMed ID: 26041750
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Switching from guaiac to immunochemical faecal occult blood test increases participation and diagnostic yield of colorectal cancer screening.
    Bretagne JF; Piette C; Cosson M; Durand G; Lièvre A
    Dig Liver Dis; 2019 Oct; 51(10):1461-1469. PubMed ID: 31151896
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A comparative study of faecal occult blood kits in a colorectal cancer screening program in a cohort of healthy construction workers.
    Shuhaibar M; Walsh C; Lindsay F; Lee N; Walsh P; O'Gorman P; Boran G; McLoughlin R; Qasim A; Breslin N; Ryan B; O'Connor H; O'Morain C
    Ir J Med Sci; 2011 Mar; 180(1):103-8. PubMed ID: 20953981
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Colorectal Cancer screening in ambulatory healthcare service clinics in Abu Dhabi, United Arab Emirates in 2015-2016.
    Almansoori A; Alzaabi M; Alketbi L
    BMC Cancer; 2021 Aug; 21(1):897. PubMed ID: 34362343
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Experience with a two-tier reflex gFOBT/FIT strategy in a national bowel screening programme.
    Fraser CG; Digby J; McDonald PJ; Strachan JA; Carey FA; Steele RJ
    J Med Screen; 2012 Mar; 19(1):8-13. PubMed ID: 22156144
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of a New-generation Fecal Immunochemical Test (FIT) With Guaiac Fecal Occult Blood Test (gFOBT) in Detecting Colorectal Neoplasia Among Colonoscopy-referral Patients.
    Guimarães DP; Fregnani JH; Reis RM; Taveira LN; Scapulatempo-Neto C; Matsushita M; Silva SRM; Oliveira CZ; Longatto-Filho A; Eklund C; Paloheimo L; Mauad E; Suovaniemi O; Syrjänen K
    Anticancer Res; 2019 Jan; 39(1):261-269. PubMed ID: 30591467
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Men with negative results of guaiac-based fecal occult blood test have higher prevalences of colorectal neoplasms than women with positive results.
    Brenner H; Hoffmeister M; Birkner B; Stock C
    Int J Cancer; 2014 Jun; 134(12):2927-34. PubMed ID: 24374771
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Seasonal variations do not affect the superiority of fecal immunochemical tests over guaiac tests for colorectal cancer screening.
    Chausserie S; Levillain R; Puvinel J; Ferrand O; Ruiz A; Raginel T; Lantieri O; Launoy G; Guittet L
    Int J Cancer; 2015 Apr; 136(8):1827-34. PubMed ID: 25195670
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Harms, benefits and costs of fecal immunochemical testing versus guaiac fecal occult blood testing for colorectal cancer screening.
    Goede SL; Rabeneck L; van Ballegooijen M; Zauber AG; Paszat LF; Hoch JS; Yong JH; Kroep S; Tinmouth J; Lansdorp-Vogelaar I
    PLoS One; 2017; 12(3):e0172864. PubMed ID: 28296927
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Negative screening colonoscopy after a positive guaiac faecal occult blood test: not a contraindication to continued screening.
    Carrera A; McClements PL; Watling C; Libby G; Weller D; Brewster DH; Carey FA; Fraser CG; Steele RJ
    Colorectal Dis; 2012 Aug; 14(8):943-6. PubMed ID: 21981347
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Superior diagnostic performance of faecal immunochemical tests for haemoglobin in a head-to-head comparison with guaiac based faecal occult blood test among 2235 participants of screening colonoscopy.
    Brenner H; Tao S
    Eur J Cancer; 2013 Sep; 49(14):3049-54. PubMed ID: 23706981
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Screening for colorectal cancer: random comparison of guaiac and immunochemical faecal occult blood testing at different cut-off levels.
    Hol L; Wilschut JA; van Ballegooijen M; van Vuuren AJ; van der Valk H; Reijerink JC; van der Togt AC; Kuipers EJ; Habbema JD; van Leerdam ME
    Br J Cancer; 2009 Apr; 100(7):1103-10. PubMed ID: 19337257
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The impact of stratifying by family history in colorectal cancer screening programs.
    Goede SL; Rabeneck L; Lansdorp-Vogelaar I; Zauber AG; Paszat LF; Hoch JS; Yong JH; van Hees F; Tinmouth J; van Ballegooijen M
    Int J Cancer; 2015 Sep; 137(5):1119-27. PubMed ID: 25663135
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Health benefits and cost-effectiveness of a hybrid screening strategy for colorectal cancer.
    Dinh T; Ladabaum U; Alperin P; Caldwell C; Smith R; Levin TR
    Clin Gastroenterol Hepatol; 2013 Sep; 11(9):1158-66. PubMed ID: 23542330
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.